Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRAL-1: Guadecitabine vs Treatment Choice in AML
NCT02348489Phase 3Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- May 2018
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of guadecitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Astex Pharmaceuticals. Primary endpoints: Complete Response up to 38 months and Overall Survival up to 38 months. Started Mar 2015; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02348489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348489.